Regeneron Pharmaceuticals' Other Non Operating Income rose 91481.48% to $176.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 10092.37%. This contributed to the annual value of $1.7 billion for FY2025, which is 10092.37% up from last year.
Latest data reveals that Regeneron Pharmaceuticals reported Other Non Operating Income of $176.0 million as of Q4 2025, which was up 91481.48% from $755.8 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Other Non Operating Income ranged from a high of $755.8 million in Q3 2025 and a low of -$183.8 million during Q1 2022
Its 5-year average for Other Non Operating Income is $169.1 million, with a median of $165.4 million in 2021.
Per our database at Business Quant, Regeneron Pharmaceuticals' Other Non Operating Income plummeted by 26878.45% in 2021 and then soared by 193780.49% in 2022.
Over the past 5 years, Regeneron Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$122.2 million in 2021, then skyrocketed by 259.82% to $195.3 million in 2022, then dropped by 1.18% to $193.0 million in 2023, then tumbled by 111.19% to -$21.6 million in 2024, then soared by 914.81% to $176.0 million in 2025.
Its last three reported values are $176.0 million in Q4 2025, $755.8 million for Q3 2025, and $442.8 million during Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value